NE3107 for Post-COVID Syndrome
(ADdRESs-LC Trial)

Recruiting in Palo Alto (17 mi)

+3 other locations

Age: 18 - 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: BioVie Inc.

Prior Safety Data

Trial Summary

What is the purpose of this trial?Long COVID is a condition where debilitating symptoms can persist for months after a COVID-19 infection. This study aims to evaluate the effects of NE3107 on several neurological symptoms reported in people with Long COVID including difficulty concentrating or remembering things ("brain fog") and fatigue. Researchers will compare NE3107 to a placebo (a look-alike substance that contains no drug) to see if NE3107 works to treat neurocognitive and fatigue symptoms of long COVID. Participants will: * Take NE3107 or a placebo twice daily for 84 days * Visit the clinic 5 times for checkups and tests and have a follow up phone call

Eligibility Criteria

This trial is for adults who are experiencing persistent symptoms like 'brain fog' and fatigue after recovering from COVID-19, known as Long COVID. Participants will be required to take medication or a placebo twice daily and attend several clinic visits.

Inclusion Criteria

I am between 18 and 64 years old.

Agree to use birth control measures

Provide voluntary consent

+3 more

Exclusion Criteria

I was in the ICU for COVID-19 treatment.

Medical history of major mental or physical illness prior to COVID-19 infection

I received a COVID-19 vaccine in the last 30 days.

Participant Groups

The study is testing NE3107, a drug aimed at treating neurological symptoms associated with Long COVID. It involves comparing the effects of NE3107 against a placebo over an 84-day period with clinic visits and follow-up calls.

2Treatment groups

Experimental Treatment

Placebo Group

Group I: NE3107Experimental Treatment1 Intervention

One 20 mg capsule containing NE3107 taken by mouth twice daily (BID)

Group II: PlaceboPlacebo Group1 Intervention

One 20 mg capsule containing placebo taken by mouth twice daily (BID)